Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSCs for Decompensated Liver Cirrhosis with HBV
NCT05442437Phase 1Completed
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Sep 2019
- Primary completion
- Jul 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of human umbilical cord mesenchymal stem cells in Liver cirrhosis (LC) (3 arms), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoints: Serum albumin at 24 weeks, Alanine aminotransferase at 24 weeks and 7 more. Started Sep 2019; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT05442437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442437.